Flexion Therapeutics Company Profile (NASDAQ:FLXN)

About Flexion Therapeutics

Flexion Therapeutics logoFlexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FLXN
  • CUSIP:
Key Metrics:
  • Previous Close: $19.27
  • 50 Day Moving Average: $19.09
  • 200 Day Moving Average: $18.62
  • 52-Week Range: $27,527,000.00 - $7.56
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.72
  • P/E Growth: 0.00
  • Market Cap: $530.45M
  • Outstanding Shares: 27,527,000
  • Beta: 1.31
Profitability:
  • Return on Equity: -51.43%
  • Return on Assets: -42.30%
Debt:
  • Debt-to-Equity Ratio: 0.17%
  • Current Ratio: 13.01%
  • Quick Ratio: 13.01%
Additional Links:
Companies Related to Flexion Therapeutics:

Analyst Ratings

Consensus Ratings for Flexion Therapeutics (NASDAQ:FLXN) (?)
Ratings Breakdown: 7 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.13)
Consensus Price Target: $29.57 (53.47% upside)

Analysts' Ratings History for Flexion Therapeutics (NASDAQ:FLXN)
Show:
DateFirmActionRatingPrice TargetDetails
2/23/2017Cantor FitzgeraldSet Price TargetBuy$37.00View Rating Details
2/7/2017BMO Capital MarketsReiterated RatingPositive$33.00View Rating Details
12/22/2016Raymond James Financial, Inc.Initiated CoverageStrong-Buy$35.00View Rating Details
11/8/2016BCSLower Price Target$0.65 -> $0.02View Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$38.00View Rating Details
6/30/2016Royal Bank of CanadaReiterated RatingBuyView Rating Details
6/30/2016Wells Fargo & CoReiterated RatingBuyView Rating Details
7/1/2016Janney Montgomery ScottReiterated RatingBuy$30.00View Rating Details
5/27/2016Needham & Company LLCReiterated RatingBuy$28.00 -> $34.00View Rating Details
9/2/2015Northland SecuritiesReiterated RatingBuy$40.00View Rating Details
3/30/2015MLV & Co.Initiated CoverageBuy$38.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Flexion Therapeutics (NASDAQ:FLXN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/7/2016Q3($0.63)($0.65)ViewListenView Earnings Details
5/12/2016Q1($0.61)($0.78)ViewListenView Earnings Details
11/9/2015Q3($0.60)($0.52)ViewListenView Earnings Details
8/6/2015Q215($0.54)($0.58)ViewN/AView Earnings Details
5/7/2015Q115($0.56)($0.43)ViewN/AView Earnings Details
3/31/2015($0.46)($0.47)ViewN/AView Earnings Details
11/13/2014Q314($0.55)($0.45)ViewN/AView Earnings Details
8/7/2014($0.52)($0.38)ViewN/AView Earnings Details
5/9/2014($0.53)($0.86)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Flexion Therapeutics (NASDAQ:FLXN)
Current Year EPS Consensus Estimate: $-2.75 EPS
Next Year EPS Consensus Estimate: $-3.37 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.59)($0.59)($0.59)
Q3 20161($0.55)($0.55)($0.55)
Q4 20161($0.69)($0.69)($0.69)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Flexion Therapeutics (NASDAQ:FLXN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Flexion Therapeutics (NASDAQ:FLXN)
Insider Ownership Percentage: 18.00%
Institutional Ownership Percentage: 62.25%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/20/2017Neil BodickInsiderSell5,000$18.35$91,750.00View SEC Filing  
12/21/2016Neil BodickInsiderSell10,000$18.46$184,600.00View SEC Filing  
12/1/2016Samuel D ColellaDirectorBuy10,000$16.38$163,800.00View SEC Filing  
11/23/2016Michael D ClaymanInsiderBuy1,667$18.41$30,689.47View SEC Filing  
11/22/2016Michael D ClaymanInsiderBuy1,666$17.95$29,904.70View SEC Filing  
11/21/2016Michael D ClaymanInsiderBuy1,666$17.90$29,821.40View SEC Filing  
11/21/2016Samuel D ColellaDirectorBuy33,333$18.00$599,994.00View SEC Filing  
6/21/2016Samuel D ColellaDirectorBuy25,504$13.71$349,659.84View SEC Filing  
6/20/2016Samuel D ColellaDirectorBuy6,778$13.84$93,807.52View SEC Filing  
6/14/2016C Ann MerrifieldDirectorBuy1,000$13.39$13,390.00View SEC Filing  
6/8/2016Samuel D ColellaDirectorBuy714,285$14.00$9,999,990.00View SEC Filing  
5/20/2016Michael D ClaymanCEOBuy2,000$10.41$20,820.00View SEC Filing  
5/19/2016Michael D ClaymanCEOBuy2,000$9.65$19,300.00View SEC Filing  
5/19/2016Neil BodickInsiderBuy850$10.00$8,500.00View SEC Filing  
5/18/2016Michael D ClaymanCEOBuy2,000$10.23$20,460.00View SEC Filing  
5/18/2016Neil BodickInsiderBuy2,100$10.20$21,420.00View SEC Filing  
5/17/2016Frederick W DriscollCFOBuy2,500$9.87$24,675.00View SEC Filing  
5/17/2016Michael D ClaymanCEOBuy2,000$9.73$19,460.00View SEC Filing  
5/17/2016Neil BodickInsiderBuy800$9.60$7,680.00View SEC Filing  
5/16/2016Frederick W DriscollCFOBuy2,500$9.19$22,975.00View SEC Filing  
5/16/2016Michael D ClaymanCEOBuy2,000$9.51$19,020.00View SEC Filing  
5/16/2016Neil BodickInsiderBuy1,250$9.22$11,525.00View SEC Filing  
9/11/2015C Ann MerrifieldDirectorBuy1,000$23.00$23,000.00View SEC Filing  
6/22/2015A/S NovoMajor ShareholderSell150,000$20.61$3,091,500.00View SEC Filing  
3/16/2015Neil BodickInsiderSell4,000$25.28$101,120.00View SEC Filing  
3/10/2015Neil BodickInsiderSell4,000$24.26$97,040.00View SEC Filing  
3/4/2015Neil BodickInsiderSell4,000$23.45$93,800.00View SEC Filing  
2/26/2015Neil BodickInsiderSell4,000$22.44$89,760.00View SEC Filing  
12/17/2014A/S NovoMajor ShareholderBuy500,000$17.00$8,500,000.00View SEC Filing  
2/18/2014A/S NovoInsiderBuy692,308$13.00$9,000,004.00View SEC Filing  
2/18/2014Bradley J Phd BolzonDirectorBuy307,692$13.00$3,999,996.00View SEC Filing  
2/18/2014Sofinnova Partners SasMajor ShareholderBuy230,769$13.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Flexion Therapeutics (NASDAQ:FLXN)
DateHeadline
streetinsider.com logoFlexion Therapeutics (FLXN) Initiates Trial to Evaluate Safety of Repeat Administration of Zilretta (NASDAQ:FLXN)
www.streetinsider.com - February 23 at 10:14 PM
News IconAre Firms & Funds Taking More Interest in Flexion Therapeutics, Inc. (NASDAQ:FLXN)? - Rockville Register (NASDAQ:FLXN)
rockvilleregister.com - February 23 at 5:13 PM
News IconStock Tracker: Earnings & Estimates for Flexion Therapeutics, Inc. (NASDAQ:FLXN) - Aiken Advocate (NASDAQ:FLXN)
aikenadvocate.com - February 23 at 5:13 PM
streetinsider.com logoFlexion Therapeutics (FLXN) Initiates Trial to Evaluate Safety of ... - StreetInsider.com (NASDAQ:FLXN)
www.streetinsider.com - February 23 at 5:13 PM
finance.yahoo.com logoFlexion Therapeutics Initiates Clinical Trial to Evaluate the Safety of Repeat Administration of Zilretta™ (FX006) in Patients with Osteoarthritis of the Knee (NASDAQ:FLXN)
finance.yahoo.com - February 23 at 5:13 PM
News IconFlexion Therapeutics Inc FLXN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:FLXN)
www.bioportfolio.com - February 22 at 10:18 AM
News IconTrading Ledger: Keeping an Eye on Flexion Therapeutics, Inc. (NASDAQ:FLXN) - Sherwood Daily (NASDAQ:FLXN)
sherwooddaily.com - February 16 at 5:09 PM
globenewswire.com logoFlexion Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release) (NASDAQ:FLXN)
globenewswire.com - February 16 at 5:09 PM
News IconInsider Activity: Is Management Buying Flexion Therapeutics, Inc. (NASDAQ:FLXN)? - Winfield Review (NASDAQ:FLXN)
winfieldreview.com - February 14 at 4:05 AM
News IconFlexion Therapeutics, Inc. (NASDAQ:FLXN) moves down at least -2.43% on its earnings reaction day - Post Analyst (NASDAQ:FLXN)
postanalyst.com - February 8 at 10:46 PM
streetinsider.com logoFlexion Therapeutics' (FLXN) NDA for Zilretta Accepted by FDA - StreetInsider.com (NASDAQ:FLXN)
www.streetinsider.com - February 8 at 10:46 PM
rttnews.com logoFLXN Gets FDA Date, KTOV In Crosshairs, It's A Thumbs Up For AMGN (NASDAQ:FLXN)
www.rttnews.com - February 8 at 4:31 AM
streetinsider.com logoFlexion Therapeutics' (FLXN) NDA for Zilretta Accepted by FDA (NASDAQ:FLXN)
www.streetinsider.com - February 7 at 6:28 PM
finance.yahoo.com logoFlexion Therapeutics Announces New Drug Application for Zilretta™ (FX006) Accepted by U.S. Food and Drug Administration (NASDAQ:FLXN)
finance.yahoo.com - February 7 at 6:28 PM
finance.yahoo.com logo7:32 am Flexion Therapeutics: FDA has accepted for filing its NDA for its lead investigational product candidate Zilretta (also known as FX006); has set PDUFA of October 6, 2017 (NASDAQ:FLXN)
finance.yahoo.com - February 7 at 6:28 PM
News IconShould You Buy Or Sell Flexion Therapeutics Inc (FLXN) On Analyst Concensus? - NewsDen (NASDAQ:FLXN)
newsden.net - February 2 at 5:47 PM
News IconAre Insiders Bumping Up Their Positions in Flexion Therapeutics, Inc. (NASDAQ:FLXN) - Wall Street Beacon (NASDAQ:FLXN)
wsbeacon.com - January 31 at 10:54 PM
News IconWhat is the Sell-side Saying About Flexion Therapeutics, Inc. (NASDAQ:FLXN)? - Aiken Advocate (NASDAQ:FLXN)
aikenadvocate.com - January 27 at 6:56 PM
News IconWhat are Brokerage Firms Saying About Flexion Therapeutics, Inc. (NASDAQ:FLXN)? - Aiken Advocate (NASDAQ:FLXN)
aikenadvocate.com - January 22 at 5:06 PM
News IconCan This Stock Hit on All Cylinders And Achieve Projections: Flexion Therapeutics, Inc. (NASDAQ:FLXN) - Prospect Journal (NASDAQ:FLXN)
prospectjournal.com - January 17 at 7:29 AM
News IconTracking Corporate Insiders: What Are They Doing With Flexion Therapeutics, Inc. (NASDAQ:FLXN) - Wall Street Beacon (NASDAQ:FLXN)
wsbeacon.com - January 17 at 7:29 AM
News IconCan This Stock Gain Traction: Flexion Therapeutics, Inc. (NASDAQ:FLXN) - Prospect Journal (NASDAQ:FLXN)
prospectjournal.com - January 9 at 6:02 PM
News IconFlexion Therapeutics Inc FLXN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:FLXN)
www.bioportfolio.com - January 8 at 5:00 PM
forbes.com logoTodd Hagopian's Top Recommendations For 2017 (NASDAQ:FLXN)
www.forbes.com - December 29 at 5:20 PM
News IconReady for an Upsurge? Analysts Chime in on Flexion Therapeutics, Inc. (NASDAQ:FLXN) - Prospect Journal (NASDAQ:FLXN)
prospectjournal.com - December 26 at 4:58 PM
marketexclusive.com logoInsider Trading Activity Flexion Therapeutics Inc. (NASDAQ:FLXN) – Insider Sold 10,000 shares of Stock (NASDAQ:FLXN)
marketexclusive.com - December 23 at 5:29 PM
finance.yahoo.com logoCoverage initiated on Flexion Therapeutics by Raymond James (NASDAQ:FLXN)
finance.yahoo.com - December 22 at 5:27 PM
News IconWilliams %R Check on Shares of Flexion Therapeutics Inc (FLXN) - StockTalk Daily (NASDAQ:FLXN)
stocktalkdaily.com - December 21 at 6:03 PM
insidermonkey.com logoShould You Avoid Flexion Therapeutics Inc (FLXN)? (NASDAQ:FLXN)
www.insidermonkey.com - December 14 at 3:55 AM
us.rd.yahoo.com logoFlexion Therapeutics Submits New Drug Application for Zilretta™ to Treat Knee Osteoarthritis Pain (NASDAQ:FLXN)
us.rd.yahoo.com - December 13 at 11:14 AM
us.rd.yahoo.com logo7:02 am Flexion Therapeutics submits a NDA for Zilretta to treat knee osteoarthritis pain (NASDAQ:FLXN)
us.rd.yahoo.com - December 13 at 11:14 AM
News IconTrading Spotlight on Shares of Flexion Therapeutics Inc (FLXN) - StockTalk Daily (NASDAQ:FLXN)
stocktalkdaily.com - December 12 at 5:25 PM
streetinsider.com logoFlexion Therapeutics (FLXN) Submits NDA for Zilretta to Treat Knee Osteoarthritis Pain - StreetInsider.com (NASDAQ:FLXN)
www.streetinsider.com - December 12 at 11:40 AM
finance.yahoo.com logoFlexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference (NASDAQ:FLXN)
finance.yahoo.com - December 9 at 10:42 AM
News IconInvestor Monitor: Narrowing in on Flexion Therapeutics, Inc. (NASDAQ:FLXN) - Marion Business Daily (NASDAQ:FLXN)
marionbusinessdaily.com - December 2 at 3:38 PM
insidermonkey.com logoShould You Buy DHI Group Inc (DHX)? (NASDAQ:FLXN)
www.insidermonkey.com - December 2 at 3:38 PM
News IconChecking the Metrics on Shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) - The Business Journal (NASDAQ:FLXN)
belmontbusinessjournal.com - November 30 at 10:36 PM
capitalcube.com logoFlexion Therapeutics, Inc. :FLXN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:FLXN)
us.rd.yahoo.com - November 29 at 5:17 PM
News IconWhat are the Technical Charts Saying About Flexion Therapeutics Inc (FLXN) - StockTalk Daily (NASDAQ:FLXN)
stocktalkdaily.com - November 23 at 10:46 PM
News IconStock Watch: FCF Score Check on Flexion Therapeutics, Inc. (NASDAQ:FLXN) - Wall Street Lion (NASDAQ:FLXN)
wslnews.com - November 21 at 10:04 AM
News IconChart Monitor: Taking a Look at Shares of Flexion Therapeutics Inc (FLXN) - StockTalk Daily (NASDAQ:FLXN)
stocktalkdaily.com - November 21 at 10:04 AM
News IconInvestor Focus: Watching Shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) - Marion Business Daily (NASDAQ:FLXN)
marionbusinessdaily.com - November 19 at 8:53 AM
biz.yahoo.com logoFLEXION THERAPEUTICS INC Files SEC form 8-K/A, Other Events, Financial Statements and Exhibits (NASDAQ:FLXN)
biz.yahoo.com - November 18 at 4:33 PM
rttnews.com logoFlexion Therapeutics Inc. (FLXN) Is Down After Offering Announcement - RTT News (NASDAQ:FLXN)
www.rttnews.com - November 18 at 8:59 AM
marketexclusive.com logoFlexion Therapeutics, Inc. (NASDAQ:FLXN) Files An 8-K Other Events - Market Exclusive (NASDAQ:FLXN)
marketexclusive.com - November 18 at 8:59 AM
News IconStocks Under Street Preference- Tokai Pharmaceuticals (NASDAQ ... - Seneca Globe (NASDAQ:FLXN)
www.senecaglobe.com - November 17 at 10:14 PM
marketexclusive.com logoFlexion Therapeutics, Inc. (FLXN) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive (NASDAQ:FLXN)
marketexclusive.com - November 17 at 10:14 PM
fool.com logoCan Flexion Therapeutics Add Some Muscle to Your Portfolio? (NASDAQ:FLXN)
www.fool.com - November 17 at 4:33 PM
News IconWhy Shares of Flexion Therapeutics, Inc., Lantheus Holdings Inc, and PDL BioPharma Inc Are Tanking Today - Fox Business (NASDAQ:FLXN)
www.foxbusiness.com - November 17 at 8:04 AM
rttnews.com logoFlexion Therapeutics Inc. (FLXN) Is Losing Ground After Offering Announcement - RTT News (NASDAQ:FLXN)
www.rttnews.com - November 17 at 8:04 AM

Social

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Where is Flexion Therapeutics' stock going? Where will Flexion Therapeutics' stock price be in 2017?

8 brokerages have issued 12 month price targets for Flexion Therapeutics' stock. Their forecasts range from $0.02 to $38.00. On average, they anticipate Flexion Therapeutics' share price to reach $29.57 in the next year.

When will Flexion Therapeutics announce their earnings?

Flexion Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Flexion Therapeutics stock?

Here are some recent quotes from research analysts about Flexion Therapeutics stock:

  • According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (2/21/2017)

  • BMO Capital Markets analysts commented, "While the company did not receive a priority review, we had not been expecting that, and had always assumed a standard 10-month review. It was good to see the FDA accept the NDA with no major issues, and we remain confident in the approval of Zilretta at the PDUFA. Reiterate our Outperform; FLXN remains a top pick." (2/7/2017)
  • Cantor Fitzgerald analysts commented, "Timing For Review: With the NDA filed in December 2016, the FDA has 60 days to decide whether to confer a Priority Review on Zilretta. Though we do see merit in prioritization, given the Fast Track designation, clean safety profile and need for longer duration, non-opioid pain options, recent FDA decisions make us question whether a reformulation will be deemed appropriate for a condensed review process." (1/17/2017)

Who owns Flexion Therapeutics stock?

Flexion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Novo A S (5.08%), Kingdon Capital Management L.L.C. (5.01%), State Street Corp (1.42%), Alyeska Investment Group L.P. (0.91%), Allianz Asset Management AG (0.59%) and Wall Street Associates (0.31%). Company insiders that own Flexion Therapeutics stock include A/S Novo, C Ann Merrifield, Frederick W Driscoll, Michael D Clayman, Neil Bodick and Samuel D Colella.

Who sold Flexion Therapeutics stock? Who is selling Flexion Therapeutics stock?

Flexion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management AG, Wall Street Associates and GRT Capital Partners L.L.C..

Who bought Flexion Therapeutics stock? Who is buying Flexion Therapeutics stock?

Flexion Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., Novo A S, Alyeska Investment Group L.P., State Street Corp, Guggenheim Capital LLC, Russell Investments Group Ltd., Raymond James Financial Services Advisors Inc. and Keybank National Association OH. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, Frederick W Driscoll, Michael D Clayman, Neil Bodick and Samuel D Colella.

How do I buy Flexion Therapeutics stock?

Shares of Flexion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Flexion Therapeutics stock cost?

One share of Flexion Therapeutics stock can currently be purchased for approximately $19.27.

Flexion Therapeutics (NASDAQ:FLXN) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Earnings History Chart

Earnings by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Dividend History Chart

Dividend Payments by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Last Updated on 2/27/2017 by MarketBeat.com Staff